This meeting aims to revisit melanoma at 360 degrees, from the diagnosis and surgery of subtle melanomas to the staging and treatment of the metastatic phase of the disease. The role of targete therapy and immunotherapy with immune checkpoint blockers will be explored, which is moving into increasingly early stages of the natural history of neoplasia: the key is to enhance the patient’s immune response against the tumor with the hope of being able to induce responses. particularly durable over time.
The decoding of the human genome in 2003 and advances in research led to the identification of genes, proteins and cellular pathways involved in the growth of cancer cells, their survival and metastasis. This has led to the identification of molecular target agents that specifically block cellular signaling pathways involved in the regulation of these processes.
The open questions and future therapeutic perspectives will be the subject of in-depth analysis and updates also deriving from the most recent international conferences. In light of the new therapeutic possibilities, aspects relating to the multidisciplinary approach will be addressed both in identifying the best therapeutic strategy for individual patients and in the correct management of adverse events.
The discussion of clinical cases will allow you to get closer to real life through interactivity in crucial decision-making junctions and addressing the critical issues that the oncologist finds in his clinic every day.